Participant flow12

How many started, completed or left each group, period by period.

1 to 12 of 12

Period	Milestone	Group	Participants
Overall Study	STARTED	Durvalumab + Tremelimumab	247
Overall Study	STARTED	Durvalumab	240
Overall Study	STARTED	Standard of Care (SoC)	249
Overall Study	Received Treatment	Durvalumab + Tremelimumab	246
Overall Study	Received Treatment	Durvalumab	237
Overall Study	Received Treatment	Standard of Care (SoC)	240
Overall Study	COMPLETED	Durvalumab + Tremelimumab	203
Overall Study	COMPLETED	Durvalumab	183
Overall Study	COMPLETED	Standard of Care (SoC)	188
Overall Study	NOT COMPLETED	Durvalumab + Tremelimumab	44
Overall Study	NOT COMPLETED	Durvalumab	57
Overall Study	NOT COMPLETED	Standard of Care (SoC)	61

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02369874/flow